What is pathophysiology of Alzheimer?

['Piŋë në ye athöörë yic']

Yeŋö ye cɔl 'pathophysiology of Alzheimer'?

Kë ye cɔl 'Alzheimer's disease (AD)'ee tuany rac apɛi, man ye tuany cɔl 'Alzheimer's disease' bɛ̈n ya cɔ̈kpiny në mïïth tɔ̈c yiic, ku ka ye tuany cɔl 'inflammation' bɛ̈n ya cɔ̈kpiny në tuany de neuron yic.

Käŋ kaa rou ke AD aye tɔ̈u de amyloid-beta (Aβ) plaques ku neurofibrillary tangles (NFTs) në nhomic.

Amyloid-beta plaques aye kek looi të cenë biäk de amyloid precursor protein (APP) ya tek yiic në enzymes ago Aβ peptides ya cak.

Peptides aye röt määt ku loi kek kä cie lëu bïk röt ya liääp ku ye kek tääu në kä kɔ̈k peei yiic, ku ye cell-to-cell communication ya cɔk riääk ku ka neuronal thou.

Käk ye cɔl 'Aβ plaques' aye kek yök ëke ye tuany tueeŋ ye tuany de AD bɛ̈n cak, ku ka ye kek cɔk loi rot në puɔ̈ɔ̈c de neurodegenerative process yic.

Neurofibrillary tangles aye röt looi të cenë mïïth ke tau röt ya looi agokë ya tɔ̈ ëke ye mïïth ke neurons.

Kä cï röt thiääk käk aye luɔɔi de microtubules cɔk liääp, ye kä thiekiic cɔk loi röt në cäth de kä ye cam ku kä kɔ̈k peei tɔ̈ në neuron yic.

Kä cï röt thiääk aye kä cï röt thiääk ke neuron bɛ̈n ya nɔ̈k.

Tuanytuɛɛny aye röt looi në guɔ̈p de raan yic.

Ajuiɛɛr de gël de guɔ̈p ee rɔt dhuɔ̈k ago ciin de Aβ plaques ku NFTs ya juak në kë de cytokines ye tuanytuɛɛny bɛ̈ibei, man lëu bï kä ye tɔ̈ në puɔ̈ɔ̈n de raan ya juak apɛi.

Kë juɛ̈c, anɔŋ kä ye nyuɔɔth lɔnadɛ̈ ke oxidative stress, mitochondrial dysfunction, ku glucose metabolism cï riääk aye kä ye kɔc cɔk tuany në AD.

Kän alëu bï neuronal ya riɔ̈ɔ̈k ku bï thou, ku bï tuaany ya juak apɛi.

Në kë de abɛ̈n, ke puɔ̈ɔ̈c de tuaany de Alzheimer ee kë rilic apɛi ye rot looi në käjuëc yiic ku ka ye naŋ kë ye yen cɔk lɔ tueŋ ku ka ye nhom määr në ye tuany kënë yic.

['Kä cï gɔ̈ɔ̈r']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Wɛ̈t cï lueel: wal']

['Wɛbthait kën ee piööc ku wël tɔ̈u thïn ku acie kë ye looi bï kɔc ke akïm ya lɛ̈k wala bï kɔc ke luɔi ya kony.']

['Wël cï kek ya lueel në ye athöör kënë yic acïï lëu bï kek ya kony agonë tuanytuɛny ya ŋic ku bï kek ya kony, ku kɔc wïc kuɔɔny de akïm adhil akïm de akïm ya thiëëc bï kek ya kony.']

['Tiɛ̈ŋë kä ye kuɔɔny de neural net looi, man ye kä ye bɛ̈n në kä cï kek ya thiëëc yiic, aye kek cɔk tɔ̈ ëke cïï kek ye deet yiic në thɛɛr juëc yiic. Cïmën de, ciin de kɔc cï kek yök ëke tuany.']

['Thïëc wɛ̈t akïmdu ka raan dɛ̈t wënë cï piöc ë pialgup wënë cï yök në biäk de tuaany. Duk wɛ̈t akïm ye kuɛ̈ɛ̈c nhom cɔk alɔn cï yen ya kë cï kueen në wɛbthait kënnë yic. Na ye tak ke yïn nɔŋ kë wïc bë yï kony në tuany, cɔl 911 ka lɔɔr në ɣön akïm tɔ̈u të thiääk ke yï në kaam thiin koor yic. Acïn akïm-tuany ye thiääk në yen në wɛbthait kënnë yic ka luɔ̈i de. BioMedLib ka kɔc cï luöi, ka raan ëbɛ̈n ye luui në yen në wɛbthait kënnë yic, acïn kë ye lueel, ye lueel ka ye lueel, në kë de wël cï kek gɔ̈ɔ̈r në ye athöör kënnë yic ka luɔ̈i de.']

['Wɛ̈t cï lueel: copyright']

['Lööŋ ke Digital Millennium Copyright Act de 1998, 17 U.S.C. § 512 (ye DMCA) ee kɔc ye käke kɔc gɔ̈t gam ke kä tɔ̈ në Internet aye käken tɔ̈ në U.S. copyright law dhoŋ kɔ̈th. ']

['Na ye gam në yith ke këriɛ̈ɛ̈c ka kä cï gɔ̈ɔ̈r tɔ̈ në wɛbthaitda ka kuɔɔnyda yic acï löŋ de gël de kä cï gɔ̈ɔ̈r dhoŋ kɔ̈u, ke yïn (ka raan ye yïn luɔ̈ɔ̈i) alëu ba ɣok tuɔ̈c wɛ̈t bï këriɛ̈ɛ̈c ka kä cï gɔ̈ɔ̈r nyaai, ka bï yïn pëën ba lɔ thïn. ']

["Wël aa bë ke tuɔɔc në athöör yic në email (tïŋ 'Rin de athöör' në biäk de email)."]

['DMCA ee wïc lɔnadɛ̈ ke kë ca lueel de kä cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i anɔŋic wël cï keek gɔ̈ɔ̈r: (1) luɛɛl de kä cï keek luɔ̈ɔ̈i cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i cï keek lueel; (2) luɛɛl de kä cï keek gɔ̈ɔ̈r cï keek lueel ku wël cï keek lueel bï keek cɔk lëu bïkë kä cï keek gɔ̈ɔ̈r yök; (3) wël bï yïn ke kɔn ya kɔɔr, nɔŋiic adrɛ̈ɛ̈rdu, namba de telepun ku adrɛ̈ɛ̈r de imeel; (4) wɛ̈t cï lueel në yï nhom lɔnadɛ̈ ke yïn ye gam ke kë cï gɔ̈ɔ̈r cï looi në kueer cï yïn ye gaam acie gam në raan de kä cï keek gɔ̈ɔ̈r cï keek luɔ̈ɔ̈i, ka raan de lööŋ, ka në luɔɔi de löŋ; ']

['(5) athöör cï yïn gätpiny në awuɔ̈c de wɛ̈t lueth, lɔnadɛ̈ ke wël tɔ̈ në athöör yic aye yith ku lɔnadɛ̈ ke yïn anɔŋ riɛl ba kä cï gɔ̈t ke lööŋ ke raan nɔŋ nhïïm ya looi në kë cï wuɔ̈ɔ̈c; ']

['Ku (6) ke ye kä cï gɔ̈t ke guɔ̈p ka kä cï gɔ̈t ke mɛ̈ɛ̈t de raan de kä cï luɔ̈ɔ̈i ka raan cï gäm riɛl bï luui në nyin de raan de kä cï luɔ̈ɔ̈i. ']

['Na këc wël cï gɔ̈ɔ̈r nhial tɔ̈u thïn kedhiɛ gɔ̈t, ke ka lëu bï këdun cï yïn gaam ya gääu.']

['Thiëc kek']

['Tuɔɔc email tënë ɣok na nɔŋ këdun thiëc/cï yïn tak.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.